Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis - PubMed (original) (raw)
Clinical Trial
. 2016 Jul 28;375(4):345-56.
doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8.
Andrew Blauvelt 1, Kim A Papp 1, Richard G Langley 1, Thomas Luger 1, Mamitaro Ohtsuki 1, Kristian Reich 1, David Amato 1, Susan G Ball 1, Daniel K Braun 1, Gregory S Cameron 1, Janelle Erickson 1, Robert J Konrad 1, Talia M Muram 1, Brian J Nickoloff 1, Olawale O Osuntokun 1, Roberta J Secrest 1, Fangyi Zhao 1, Lotus Mallbris 1, Craig L Leonardi 1; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group
Collaborators, Affiliations
- PMID: 27299809
- DOI: 10.1056/NEJMoa1512711
Free article
Clinical Trial
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Kenneth B Gordon et al. N Engl J Med. 2016.
Free article
Abstract
Background: Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment of moderate-to-severe psoriasis. We report the 60-week data from the UNCOVER-2 and UNCOVER-3 trials, as well as 12-week and 60-week data from a third phase 3 trial, UNCOVER-1.
Methods: We randomly assigned 1296 patients in the UNCOVER-1 trial, 1224 patients in the UNCOVER-2 trial, and 1346 patients in the UNCOVER-3 trial to receive subcutaneous injections of placebo (placebo group), 80 mg of ixekizumab every 2 weeks after a starting dose of 160 mg (2-wk dosing group), or 80 mg of ixekizumab every 4 weeks after a starting dose of 160 mg (4-wk dosing group). Additional cohorts in the UNCOVER-2 and UNCOVER-3 trials were randomly assigned to receive 50 mg of etanercept twice weekly. At week 12 in the UNCOVER-3 trial, the patients entered a long-term extension period during which they received 80 mg of ixekizumab every 4 weeks through week 60; at week 12 in the UNCOVER-1 and UNCOVER-2 trials, the patients who had a response to ixekizumab (defined as a static Physicians Global Assessment [sPGA] score of 0 [clear] or 1 [minimal psoriasis]) were randomly reassigned to receive placebo, 80 mg of ixekizumab every 4 weeks, or 80 mg of ixekizumab every 12 weeks through week 60. Coprimary end points were the percentage of patients who had a score on the sPGA of 0 or 1 and a 75% or greater reduction from baseline in Psoriasis Area and Severity Index (PASI 75) at week 12.
Results: In the UNCOVER-1 trial, at week 12, the patients had better responses to ixekizumab than to placebo; in the 2-wk dosing group, 81.8% had an sPGA score of 0 or 1 and 89.1% had a PASI 75 response; in the 4-wk dosing group, the respective rates were 76.4% and 82.6%; and in the placebo group, the rates were 3.2% and 3.9% (P<0.001 for all comparisons of ixekizumab with placebo). In the UNCOVER-1 and UNCOVER-2 trials, among the patients who were randomly reassigned at week 12 to receive 80 mg of ixekizumab every 4 weeks, 80 mg of ixekizumab every 12 weeks, or placebo, an sPGA score of 0 or 1 was maintained by 73.8%, 39.0%, and 7.0% of the patients, respectively. Patients in the UNCOVER-3 trial received continuous treatment of ixekizumab from weeks 0 through 60, and at week 60, at least 73% had an sPGA score of 0 or 1 and at least 80% had a PASI 75 response. Adverse events reported during ixekizumab use included neutropenia, candidal infections, and inflammatory bowel disease.
Conclusions: In three phase 3 trials involving patients with psoriasis, ixekizumab was effective through 60 weeks of treatment. As with any treatment, the benefits need to be weighed against the risks of adverse events. The efficacy and safety of ixekizumab beyond 60 weeks of treatment are not yet known. (Funded by Eli Lilly; UNCOVER-1, UNCOVER-2, and UNCOVER-3 ClinicalTrials.gov numbers NCT01474512, NCT01597245, and NCT01646177, respectively.).
Comment in
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Gordon KB, Colombel JF, Hardin DS. Gordon KB, et al. N Engl J Med. 2016 Nov 24;375(21):2102. doi: 10.1056/NEJMc1610828. N Engl J Med. 2016. PMID: 27959738 No abstract available. - Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Egeberg A. Egeberg A. N Engl J Med. 2016 Nov 24;375(21):2101-2102. doi: 10.1056/NEJMc1610828. N Engl J Med. 2016. PMID: 27959739 No abstract available.
Similar articles
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial. - Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M. Blauvelt A, et al. Am J Clin Dermatol. 2017 Apr;18(2):273-280. doi: 10.1007/s40257-016-0246-9. Am J Clin Dermatol. 2017. PMID: 28074446 Free PMC article. Clinical Trial. - Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI, Hooft L. Spuls PI, et al. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. doi: 10.1111/bjd.12025. Br J Dermatol. 2012. PMID: 23013312 - Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.
Syed YY. Syed YY. Am J Clin Dermatol. 2017 Feb;18(1):147-158. doi: 10.1007/s40257-017-0254-4. Am J Clin Dermatol. 2017. PMID: 28138946 Review. - Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis.
Shelton SK, Bai SR, Jordan JK, Sheehan AH. Shelton SK, et al. Ann Pharmacother. 2019 Mar;53(3):276-284. doi: 10.1177/1060028018799982. Epub 2018 Sep 6. Ann Pharmacother. 2019. PMID: 30187769 Review.
Cited by
- Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection.
Jauregui W, Abarca YA, Ahmadi Y, Menon VB, Zumárraga DA, Rojas Gomez MC, Basri A, Madala RS, Girgis P, Nazir Z. Jauregui W, et al. Cureus. 2024 Sep 3;16(9):e68569. doi: 10.7759/cureus.68569. eCollection 2024 Sep. Cureus. 2024. PMID: 39364475 Free PMC article. Review. - Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study.
Li X, Ding Y, Zhang C, Lu Y, Li F, Pan W, Guo S, Li J, Zhao B, Zheng J. Li X, et al. Adv Ther. 2024 Sep 30. doi: 10.1007/s12325-024-02976-w. Online ahead of print. Adv Ther. 2024. PMID: 39347926 - Value of PASI90 Versus Merit-Based Incentive Payment System Efficacy Measures.
Hawkes JE, Reis P, Lin CY, Muram T, Eastman WJ. Hawkes JE, et al. J Psoriasis Psoriatic Arthritis. 2022 Jul;7(3):140-149. doi: 10.1177/24755303221082623. Epub 2022 Apr 19. J Psoriasis Psoriatic Arthritis. 2022. PMID: 39296534 Free PMC article. - Periodontitis in Psoriatic Patients: Epidemiological Insights and Putative Etiopathogenic Links.
Di Spirito F, Di Palo MP, Rupe A, Piedepalumbo F, Sessa A, De Benedetto G, Russo Barone S, Contaldo M. Di Spirito F, et al. Epidemiologia (Basel). 2024 Jul 26;5(3):479-498. doi: 10.3390/epidemiologia5030033. Epidemiologia (Basel). 2024. PMID: 39189252 Free PMC article. Review. - Ixekizumab Improved Refractory Erythrodermic Psoriasis with Comorbid Diffuse Alopecia: A Case Report with 52-Week Follow-Up.
Song B, Liu X, Jin H. Song B, et al. Clin Cosmet Investig Dermatol. 2024 Aug 8;17:1811-1814. doi: 10.2147/CCID.S471582. eCollection 2024. Clin Cosmet Investig Dermatol. 2024. PMID: 39139845 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials